NEW YORK (GenomeWeb News) – Enzo Biochem will seek CLIA waivers for GeneNews' colorectal cancer test in New York and New Jersey and market the test in those states, under an agreement announced by the firms today.

Enzo plans to validate and seek approval in New York, New Jersey, and under CLIA requirements for the ColonSentry blood-based test for colorectal cancer risk. It also intends to market and secure third-party reimbursement for the test. Enzo said it hopes to make the test available in the second half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.